Featured Article Repair Biotechnologies Announces Positive Pre-IND Meeting with FDA for REP-0003 to Treat Homozygous Familial Hypercholesterolemia Read more
Featured Article Repair Biotechnologies and Genevant Sciences to Collaborate to Develop mRNA-LNP Therapy with First-in-Class Potential to Turn Back Atherosclerosis Read more
Featured Article Repair Biotechnologies Announces Appointment of Noted Cardiologists to Scientific Advisory Board Read more
Repair Biotechnologies Announces Positive Pre-IND Meeting with FDA for REP-0003 to Treat Homozygous Familial Hypercholesterolemia
Repair Biotechnologies and Genevant Sciences to Collaborate to Develop mRNA-LNP Therapy with First-in-Class Potential to Turn Back Atherosclerosis
Repair Biotechnologies Announces Positive Pre-IND Meeting with FDA for REP-0003 to Treat Homozygous Familial Hypercholesterolemia Read more
Repair Biotechnologies and Genevant Sciences to Collaborate to Develop mRNA-LNP Therapy with First-in-Class Potential to Turn Back Atherosclerosis Read more
Repair Biotechnologies Announces Appointment of Noted Cardiologists to Scientific Advisory Board Read more
Repair Biotechnologies Announces 48% Reversal of Atherosclerotic Plaque Lipids in a Preclinical Mouse Study Read more